+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Vertex triple combinations

  • ID: 4775388
  • Report
  • September 2018
  • Region: Global
  • 20 pages
  • Datamonitor Healthcare
1 of 2

Enquire about COVID-19 updates for this product.

Enquire Now
Drug Overview
Vertex is developing several triple combination regimens in order to further its cystic fibrosis portfolio with the best such regimen, combining a new CFTR corrector compound with its tezacaftor + ivacaftor backbone, which is now approved as Symdeko. New CFTR correctors evaluated so far include VX-152, VX-440, VX-445, and VX-659, with Vertex targeting VX-445 and VX-659 for further development.
Note: Product cover images may vary from those shown
2 of 2
CONTENTS

OVERVIEW
Drug Overview
Product Profiles
Vertex triple combination program : Cystic fibrosis

LIST OF FIGURES
Figure 1: Vertex triple combination program for cystic fibrosis – SWOT analysis
Figure 2: The authors drug assessment summary of Vertex triple combination program for cystic fibrosis
Figure 3: The authors drug assessment summary of Vertex triple combination program for cystic fibrosis
Figure 4: Vertex triple combination program sales for cystic fibrosis across the US and five major EU markets, by country, 2016–25

LIST OF TABLES
Table 1: Vertex triple combination program drug profile
Table 2: Vertex triple combination program Phase II data in cystic fibrosis
Table 3: Vertex triple combination program Phase III data in cystic fibrosis
Table 4: Vertex triple combination program sales for cystic fibrosis across the US and five major EU markets, by country ($m), 2016–25
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll